New partnership between Christiana Care’s Gene Editing Institute and NovellusDx speeds progress toward personalized cancer medicine

The Gene Editing Institute has licensed its innovative gene editing technology to NovellusDx to improve the efficiency and speed of NovellusDx’s cancer diagnostic screening tools. With the use of advanced gene editing technology, NovellusDx will be able to identify the genetic mechanism responsible for both the onset and progression of many types of cancer and determine the most effective cancer therapy. NovellusDx will pay royalties to Christiana Care for ten years for the use of its innovative gene editing technology.

read more

NovellusDx is the winner of CiMED 2017 Startup Competition

California, US. CiMED connects Israeli MedTech companies to the Silicon Valley health and medical technology ecosystem, including investors, health care providers, payers, IT companies, corporations and thought leaders. NovellusDx CEO, Haim Gil-AD presented during the...

read more

NovellusDx Registers Another Patent On FACT™

Jerusalem, Israel Last month NovellusDx was granted Israel Patent #239624 For METHODS AND SYSTEMS FOR IDENTIFYING PATIENT SPECIFIC DRIVER MUTATIONS for its Functional Annotation of Cancer Treatment technology. The patent, which will remain in force until 2034, adds to...

read more

NovellusDx presenting in CiMED

California, US. NovellusDx will be presenting on June 7 as part of the Israeli delegation organized by the California Israel Chamber of Commerce. CiMED connects Israeli MedTech companies to the Silicon Valley health and medical technology ecosystem, including...

read more

NovellusDx in MIXiii Biomed 2017

Tel Aviv, Israel. NovellusDx abstract, titled “NovellusDx Functional Oncology Diagnostics” has been  accepted for oral presentation by the scientific committee of the MIXiii Biomed 2017 to be held in Tel Aviv, Israel on May 23, 2017 at 12:25 PM in a company...

read more